Latest from research and the clinic.
New trial results, patient questions answered, India updates, and plain-language commentary on Lutetium therapy. Updated weekly. Reviewed by medical oncologists.
PSMAfore: Lu-177 PSMA therapy before chemotherapy shows benefit.
The PSMAfore trial — published in 2024 — tested Lu-177 PSMA therapy in men whose prostate cancer had progressed on hormone therapy but who hadn't yet had chemotherapy. The results are reshaping when patients should consider Lutetium therapy.
What Is Lu-177 Therapy? A Patient-Friendly Guide to How It Works, What to Expect, and Whether It Might Be Right for You
Lu-177 PSMA therapy uses a targeted radioactive molecule to find and destroy advanced prostate cancer cells while mostly sparing healthy tissue. This plain-language guide explains how it works, what a treatment cycle looks like, common side effects, and radiation safety at home.
How we choose what to write about
We focus on three kinds of content:
- Trial results that change practice - plain-language summaries of new evidence, with honest framing of what it does and doesn't mean
- Patient questions we hear repeatedly - taking the most common navigator-conversation questions and answering them publicly
- India updates - new centers, new approvals, new policies that affect Indian and India-bound patients
Every clinical post is reviewed by an oncologist or nuclear medicine physician before publication.
Have a specific question about your situation?
A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.
Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.